Searchable abstracts of presentations at key conferences in endocrinology

ea0016p467 | Neuroendocrinology | ECE2008

Starting dose of 10 mg Octreotide-LAR appears ineffective for biochemical control in the majority of acromegalic patients: interim analysis from the OASIS trial

Petersenn Stephan , Tarasov Alexander , Gu Feng , Kim Sungwoon , Mercado Moises , Rogozinski Amelia , Bouterfa Hakim , David Kristin , Silva Antonio , Greenman Yona

Octreotide LAR (SMS-LAR) is available in 10, 20 and 30 mg dosing. The relation-ship between SMS-LAR starting dose and GH, IGF-I and symptoms was exam-ined. The Observational Acromegaly Study on Impact of Sandostatin LAR (OASIS) collects data on GH, IGF-I, symptoms, safety and tolerability in recently diagnosed acromegalic patients. Data are collected under normal practice conditions over 12 mos. Eight hundred and sixty patients from 138 centers in 23 countries are enrolled; 35...